Clinical trial / 2011
A health maintenance protocol with telomerase activator TA-65 reduced senescent cytotoxic T cells and the percentage of short telomeres over 1 year.
An analysis of the first year of data from a commercial health maintenance program (PattonProtocol-1) evaluated the effects of 10-50 mg daily of the telomerase activator TA-65 along with a dietary supplement pack and physician counseling. In vivo, there were significant declines in the percent of senescent cytotoxic (CD8(+)/CD28(-)) T cells at 6, 9, and 12 months (p = 0.018, 0.0024, and 0.0062) and natural killer cells at 6 and 12 months (p = 0.028 and 0.00013), mostly in CMV-seropositive subjects. In a subset measured at baseline and 12 months, mean telomere length did not increase, but the percent of short (<4 kbp) telomeres significantly decreased (p = 0.037). No adverse events were attributed to the protocol, and controlled randomized trials are planned to assess TA-65-specific effects.
- Study type
- Intervention study
- Who was studied
- Participants in a commercial health maintenance program (PattonProtocol-1)
- What was measured
- Immune cell proportions, telomere length distribution, and adverse events
THE PAPER
A natural product telomerase activator as part of a health maintenance program.
Harley CB, Liu W, Blasco M, Vera E, Andrews WH, Briggs LA, Raffaele JM. Rejuvenation Res, 2011.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.